Pharmacist and certified radiopharmacist at Vienna General Hospital (AKH).
Dr. Markus Mitterhauser is a radiopharmacist with recognized expertise in theranostics, molecular imaging, and the development and clinical application of modern radiopharmaceuticals for PET imaging and radionuclide therapy.
He has been affiliated with the Medical University of Vienna for many years, where he is actively involved in both clinical nuclear medicine and scientific research. A particular focus of his work lies in radiopharmacy, quality assurance in nuclear medicine procedures, and the advancement of theranostic concepts.
Dr. Mitterhauser is the author of more than 270 scientific publications and is involved in numerous national and international research collaborations. His work makes an important contribution to precision theranostics and to the continuous advancement of modern nuclear medicine methodologies.
Beyond routine patient care and research, he is also deeply committed to academic teaching at the University of Vienna, the Medical University of Vienna, and various universities of applied sciences, thereby making an important contribution to the education and training of younger colleagues.
In addition to his clinical and academic activities, Dr. Markus Mitterhauser is also directly committed to supporting people with prostate cancer. In 2020, he founded the PATIO initiative to provide targeted support and guidance for affected individuals. PATIO aims to improve the quality of life in everyday living with prostate cancer together with a team of people personally affected by the disease. To further expand these efforts and secure the necessary resources, he founded the PATIO association at the end of 2025.
At Theranosticum Vienna, Dr. Mitterhauser contributes his scientific and clinical-pharmaceutical expertise to the careful planning, execution, and interpretation of nuclear medicine examinations. As a pharmacist, he also ensures that therapeutic radiopharmaceuticals are prepared and made available to patients in the highest possible quality.
Memberships
- European Association of Nuclear Medicine (EANM)
- Society of Nuclear Medicine and Molecular Imaging (SNMMI)
- Member of the Scientific Advisory Board of the Helmholtz-Zentrum Dresden-Rossendorf
- Member of the Executive Board of the Austrian Society of Nuclear Medicine and Theranostics as representative and spokesperson for the scientific disciplines.
Languages
- German
- English
Professional Background
Dr. Markus Mitterhauser graduated in 1988 from the Humanistic Grammar School Kollegium Kalksburg in Vienna and subsequently began studying pharmacy. In 1998, he obtained his license as a pharmacist, and in 2003 he earned a doctorate in natural sciences from the University of Vienna. In 2006, he completed his habilitation in radiopharmacy at the Medical University of Vienna, and in the same year also obtained his certification as a hospital pharmacist. Between 1998 and 2024, he served as Head of the Isotope Pharmacy.
From 2016 to 2023, Markus Mitterhauser was Director of the Ludwig Boltzmann Institute for Applied Diagnostics. Motivated by personal experiences with cancer, he founded the initiative Patient Involvement in Oncology (PATIO) in 2020, focusing on improving the quality of life of people with prostate cancer and involving them directly in scientific research.
In 2022, Markus Mitterhauser was appointed Endowed Professor for Applied Diagnostics at the University of Vienna, a professorship that was transferred to the Medical University of Vienna in 2025. Since January 2026, Markus Mitterhauser has served as Coordinator for Radiopharmacy and Nuclear Medicine at the newly established Center for Translational Medicine (CTM) of the Medical University of Vienna.
Publications
- Schmitl S, Kretschmer-Chott E, Patronas EM, Kramer G, Ritt P, Fuchs E, Weisbrod M, Nics L, Mitterhauser M, Hacker M.
Efficacy, Safety, Blood Kinetics, and 213Bi Distribution Studies of [225Ac]Ac-SibuDAB in Prostate Cancer Patients
J Nucl Med. 2025 Aug 1;66(8):1239-1244. doi: 10.2967/jnumed.125.269655.PMID: 40473466 - Schmitl S, Raitanen J, Witoszynskyj S, Patronas EM, Nics L, Ozenil M, Weissenböck V, Mindt TL, Hacker M, Wadsak W, Brandt MR, Mitterhauser M.
Quality Assurance Investigations and Impurity Characterization during Upscaling of [177Lu]Lu-PSMAI&T
Molecules. 2023 Nov 21;28(23):7696. doi: 10.3390/molecules28237696.PMID: 38067427 - Raitanen J, Palm L, Hacker M, Balber T, Mitterhauser M.
The importance of radiochemical purity: Cellular binding and internalization of different radiometal chlorides in prostate cancer cells
Nucl Med Biol. 2024 Nov-Dec;138-139:108949. doi: 10.1016/j.nucmedbio.2024.108949. Epub 2024 Sep 7.PMID: 39284237 - Raitanen J, Barta B, Fuchs H, Hacker M, Balber T, Georg D, Mitterhauser M.
Radiobiological Assessment of Targeted Radionuclide Therapy with [177Lu]Lu-PSMA-I&T in 2D vs. 3D Cell Culture Models
Int J Mol Sci. 2023 Nov 30;24(23):17015. doi: 10.3390/ijms242317015.PMID: 38069337 - Raitanen J, Barta B, Hacker M, Georg D, Balber T, Mitterhauser M.
Comparison of Radiation Response between 2D and 3D Cell Culture Models of Different Human Cancer Cell Lines
Cells. 2023 Jan 18;12(3):360. doi: 10.3390/cells12030360.PMID: 36766704 - Al Jalali V, Wasinger G, Rasul S, Grubmüller B, Wulkersdorfer B, Balber T, Mitterhauser M, Simon J, Hacker M, Shariat S, Egger G, Zeitlinger M.
Consecutive Prostate-Specific Membrane Antigen (PSMA) and Antigen Receptor (AR) PET Imaging Shows Positive Correlation with AR and PSMA Protein Expression in Primary Hormone-Naïve Prostate Cancer
J Nucl Med. 2023 Jun;64(6):863-868. doi: 10.2967/jnumed.122.264981. Epub 2023 Jan 19.PMID: 36657982 - Zisser L, Yu J, Oszwald A, Wollenweber T, Kretschmer-Chott E, Grubmüller B, Kramer G, Shariat SF, Mitterhauser M, Vraka C, Hacker M, Haug AR, Rasul S.
Response to [ 177 Lu]Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients presenting with only lymph node metastases
Nucl Med Commun. 2022 Nov 1;43(11):1113-1120. doi: 10.1097/MNM.0000000000001611. Epub 2022 Sep 19.PMID: 36120814 - Huebner N, Rasul S, Baltzer P, Clauser P, Hermann Grubmüller K, Mitterhauser M, Hacker M, Heidenreich A, Rajwa P, Fajkovic H, Shariat SF, Grubmüller B.
Feasibility and Optimal Time Point of [68Ga]Gallium-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography Imaging in Patients Undergoing Cytoreductive Surgery After Systemic Therapy for Primary Oligometastatic Prostate Cancer: Implications for Patient Selection and Extent of Surgery
Eur Urol Open Sci. 2022 May 5;40:117-124. doi: 10.1016/j.euros.2022.04.003. eCollection 2022 Jun.PMID: 35638090 - Rasul S, Hartenbach M, Wollenweber T, Kretschmer-Chott E, Grubmüller B, Kramer G, Shariat S, Wadsak W, Mitterhauser M, Pichler V, Vraka C, Hacker M, Haug AR.
Prediction of response and survival after standardized treatment with 7400 MBq 177Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1650-1657. doi: 10.1007/s00259-020-05082-5. Epub 2020 Oct 30.PMID: 33128131 - Grubmüller B, Jahrreiss V, Huebner N, Mitterhauser M, Stangl-Kremser J, Grubmüller KH, Baltzer P, Hacker M, Goldner G, Shariat SF, Rasul S.
Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [68Ga]Ga-PSMA ligand PET/CT(MRI)
Nucl Med Commun. 2022 Nov 1;43(11):1113-1120. doi: 10.1097/MNM.0000000000001611. Epub 2022 Sep 19.PMID: 36120814
“For me, precision comes first. Every step of the examination must be carefully planned and reliably executed so that patients can feel confident and the results are truly reliable.”
Dr. Markus Mitterhauser
We take time for what matters - your care
If you have questions or would like to schedule an appointment, we are here for you.
In a personal consultation, we discuss your concerns in a calm setting and outline the next steps together.
Our team will get back to you promptly and support you competently and reliably - from the first contact through to your therapy appointment.
